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INTRODUCTION
The blood remaining in the placenta and umbilical cord
following birth contains hematopoietic precursors and has
become an important alternative source for transplantation
of hematopoietic stem cells [1,2]. Due to the limited number
of hematopoietic stem cells in a given cord blood unit, cord
blood transplants have been associated with delayed hemato-
poietic engraftment, especially in larger recipients [3].
Because the marrow stromal cells are an important
source of cytokines and microenvironmental structural sup-
port for hematopoiesis, the outcome of hematopoietic stem
cell transplantation could be improved by coengraftment of
the nonhematopoietic marrow elements in addition to the
hematopoietic precursors [4,5]. These cells could supple-
ment the marrow microenvironment, thus impacting the
rapidity and quality of hematopoiesis posttransplantation.
Additionally, in a clinical setting where the patient has a
defective stromal microenvironment, this cell population
could potentially replace the stromal cells and result in
improved hematopoiesis.
The stromal cell population in bone marrow (BM) has
been the focus of much attention since it has been shown
that this cell population can be expanded and differentiated
into cells with the phenotype of bone, cartilage, muscle,
stroma, neural, and fat cells [6-16]. Various studies have
failed to demonstrate the presence of this population in
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ABSTRACT
The stromal cell population in bone marrow has been the focus of much attention since it has been shown that this
cell population can be expanded and differentiated into cells with the phenotype of bone, cartilage, muscle, stroma,
neural, and fat cells. We evaluated umbilical cord blood (UCB) for the presence of these cells. From the mononu-
clear fraction of UCB, we demonstrated the presence of a subset of cells that have been maintained in continuous
culture for more than 6 months (>10 passages). These adherent cell populations express adhesion molecules CD13+,
CD29+, and CD44+, but not antigens of hematopoietic differentiation. Exposure of these cells to osteogenic agents
resulted in an increase in expression of alkaline phosphatase and the appearance of hydroxyapatite nodules by Von
Kossa staining. Incubation with adipogenic agents resulted in morphological change and staining with Oil Red O. In
addition, when exposed to basic fibroblast growth factor and human epidermal growth factor the cells underwent
changes consistent with cells of neural origin. These changes were demonstrated by a combination of immunofluo-
rescent labeling and Western immunoblots for neural-specific markers. Thus, similar to what has been previously
reported with bone marrow, cord blood contains a population of cells that can be expanded in culture and are able
to express the phenotype of multiple lineages. Cord blood multilineage cells are slower to establish in culture, have
a lower precursor frequency and a lower level of bone antigen expression, and lack constitutive expression of neural
antigens when compared to bone marrow, suggesting a more primitive population. Cord blood may prove to be a
new source of cells for cellular therapeutics for stromal, bone, and, potentially, neural repair.
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umbilical cord blood (UCB) [17-19]. Recently, however, sev-
eral groups have reported bone and fat differentiation capac-
ity from cord blood–derived nonhematopoietic cells [20-22].
We sought to evaluate whether the stromal precursor
cells were present in UCB and, if so, to characterize them.
Our approach was to culture the cellular component of
whole cord blood in a growth medium that does not support
hematopoiesis. We present data that demonstrate the
presence within cord blood of a rare cell population with




Umbilical cord blood was obtained in accordance with
an IRB-approved protocol for the St. Louis Cord Blood
Bank. The blood was collected into a 250-mL standard
blood collection bag (Baxter, Deerfield, IL) containing
citrate-phosphate-dextrose anticoagulant. The cord blood
was processed within 24 hours of collection and the
mononuclear fraction was isolated using standard Ficoll-
Hypaque techniques (Lymphoprep; Nycomed, Oslo, Nor-
way). The cells were cultured in growth medium (Dulbec-
co’s Modified Eagle Media–low glucose [Gibco BRL,
Rockville, MD] with the addition of 10% fetal bovine serum
[Stem Cell Technologies, Vancouver, BC], 2 mmol/L L-glu-
tamine [Gibco BRL] and 1% penicillin-streptomycin
[Gibco BRL]) at 37°C and various CO2 concentrations of
5% to 8%. Cells were initially plated into 10 to 175 cm2
tissue culture slides (Fisher Scientiﬁc, Pittsburgh, PA) and
flasks (Corning, Corning, NY) at a density of 1 × 106
mononuclear cells (MNCs)/cm2. The medium was changed
after 1 day of culture. Half the medium was changed weekly
thereafter. Cells were passaged by trypsinization (0.05%
trypsin/EDTA [ethylenediaminetetraacetic acid] solution;
Gibco BRL) upon reaching 50% to 60% conﬂuence (5000-
6000 cells/cm2) and replated at a density of 1000 to 2000 cells/cm2.
The BM mesenchymal stem cells (MSCs) were obtained
from residual cells recovered from filters of BM harvests.
The ﬁlters were rinsed with Dulbecco’s phosphate buffered
saline (DPBS; Gibco BRL) and the cells isolated by Ficoll
gradient centrifugation. Additional BM MSCs, a gift from
Osiris Therapeutics, Baltimore, MD, were also studied. The
cells were grown under the same culture conditions as
described above.
The precursor frequency of the cord blood NHPs was
measured using a modified colony-forming unit–fibroblast
(CFU-F) assay. Mononuclear cells from the primary cul-
tures were plated into either 96-well plates, initial concen-
tration 5.0 × 106 MNCs per 0.32 cm2, in the ﬁrst 8 wells and
then serially diluted (1:3); or into tissue culture ﬂasks at a
density of 1 × 106 MNCs/cm2. In both cases, cells were
grown for 30 days and then colonies were counted by
inverted phase microscopy. A colony was deﬁned as a cluster
of 20 or more cells. For measurement of growth over the
length of time in culture, cells were suspended with a
trypsin/EDTA solution, counted with a hemocytometer, and
replated at defined time points. When the cells reached
50% to 60% conﬂuence, they were replated at a density of
1000 to 2000 cells/cm2.
Flow Cytometry
The cells were trypsinized, then incubated with fluo-
rochrome-conjugated antibody on ice for 30 minutes in the
dark, rinsed twice with cold DPBS and fixed with freshly
prepared cold 2% paraformaldehyde (Sigma), and then ana-
lyzed using a Coulter Epics XL-MCL ﬂow cytometer (Beck-
man Coulter, Brea, CA) with a minimum of 10,000 events
counted. The antibodies used were CD2-FITC, CD16-
FITC, CD19-FITC, isotype controls (Beckman Coulter);
CD3-PE, CD13-PE, CD14-PC5, CD24-PE, CD29-FITC,
CD33-PE, CD34-ECD, CD38-FITC, CD44-FITC,
CD45-PE, CD90-FITC (Immunotech, Marseille, France);
CD15-FITC, glycophorin A-FITC (DAKO, Carpinteria,
CA); CD106-FITC (R&D Systems, Minneapolis, MN); and
CD105-FITC or PE, CD166-FITC (Research Diagnostics,
Flanders, NJ).
Hematopoietic CFU Assay
Hematopoiesis was assessed in duplicate using a semi-
solid clonogenic assay (Terry Fox Laboratories, Vancouver,
Canada). The quantity of 2 × 104 cells was inoculated into
3.0 mL of Iscove’s methylcellulose medium (Methocult
H4434; Stem Cell Technology, Vancouver, Canada) and
divided equally into 2 wells (6-well, Falcon). The plates
were incubated (37°C, 5% CO2) for 2 weeks, after which
CFU–granulocyte-macrophage (GM), CFU–granulocyte-
erythroid–macrophage monocyte-megakaryocyte (GEMM),
and erythroid burst-forming units (BFU-E) were counted
using an inverted microscope.
Osteogenic Potential
Once sufﬁcient numbers of cells were grown from UCB
(passage 4 or greater), cells were plated at 1500 to 4000
cells/cm2 in growth medium. Osteogenesis medium
(growth medium with the addition of 0.1 µmol/L dexam-
ethasone [Sigma], 0.05 mmol/L ascorbic acid-2-phosphate
[Sigma] and 10 mmol/L β-glycerophosphate [Sigma]) was
applied 24 hours after plating [23]. Medium changes were
performed every 3 to 4 days. Osteogenesis was assessed on
days 7, 10, and 14. The expression of alkaline phosphatase
was measured using the Sigma Diagnostics kit 86 following
the manufacturer’s protocol. The presence of hydroxyap-
atite [(Ca10(PO4)6(OH)2)] nodules was visualized with a 2%
silver nitrate solution (Sigma). The calcium in the cultures
was extracted using a 1N HCl solution (Sigma) and levels
assessed by colorimetric determination at 575 nm using
known calcium standards (Sigma) following the manufac-
turer’s protocol.
Adipogenic Potential
Passage 2, 3, 4, 7, and 8 cells were plated at 2000 cells/cm2
in adipogenesis medium (growth medium with the addition
of 1 µmol/L dexamethasone, 5 µg/mL insulin, 0.5 mmol/L
isobutylmethylxanthine, and 60 µmol/L indomethacin) [21].
The cells were fed weekly. After 2 weeks in adipogenic
medium, cells were examined for the presence of neutral
lipid vacuoles that stained with Oil Red O.
Expression of Neural Specific Markers
Passage 4 or greater cells were plated at 1000 to 2000
cells/cm2 in complete medium with the addition of 20 ng/mL
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basic ﬁbroblast growth factor (bFGF) (Sigma) and 20 ng/mL
human epidermal growth factor (hEGF) (Gibco) for 7 days.
Western blot was performed to detect the presence of β-
tubulin III (TuJ1) and glial ﬁbrillary acidic protein (GFAP).
The cells were trypsinized, pelleted, and then added to a
lysis buffer containing protease inhibitors (50 mmol/L
HEPES, 400 mmol/L NaCl, 2 mmol/L EDTA, 0.1%
NP-40, 1 mmol/L DTT, 1 µg/mL aprotinin, 1 µg/mL leu-
peptin, and 50 µg/mL PMSF, all from Sigma). The suspen-
sion was centrifuged at 16,000g at 4°C for 3 minutes and the
supernatant discarded. Protein concentrations were deter-
mined by BioRad assay. Total protein used was 10 µg for the
UCB and BM samples and 2 µg for the positive control.
The proteins were transferred using the semi-dry method
and were immunoblotted with antibodies followed by the
application of horseradish peroxidase conjugated secondary
antibodies, which were detected by chemiluminescence
(Super Signal Chemiluminesent Substrate; Pierce, Rock-
ford, IL). The mouse monoclonal antibodies used were
against TuJ1 (dilution 1:1000; Covance, Richmond, CA)
and GFAP (dilution 1:300, Advanced Immuno Chemical,
Long Beach, CA). The isolates of the immortalized pro-
genitor cell line C17.2 (gift of Dr. E. Snyder, Harvard Uni-
versity) were used as a positive control.
For the immunocytochemical TuJ1 and GFAP label-
ing, cells (BM passage 5, 6; cord blood passage 6, 7, 8)
were fixed for 1 minute in –20°C methanol (Sigma) and
rinsed 3 times, for 3 minutes each rinse, with cold DPBS.
The cells were blocked with 2% fish gel (Sigma) with 2%
goat serum (Vector Laboratories, Burlingame, CA) in
DPBS for 1 hour at room temperature. Primary antibodies
against TuJ1 (dilution 1:500; Covance) and GFAP (dilution
1:100; mouse anti-human MoAb [Advanced Immuno
Chemical] or rabbit polyclonal [Sigma]) were incubated
overnight at 4°C. The slides were rinsed 3 times with the
blocking solution and were incubated at room temperature
for 1 hour with the secondary antibodies, Oregon Green
(dilution 1:300; Molecular Probes, Eugene, OR) or Alexa
Fluor 43 (dilution 1:300; Molecular Probes), followed by 3
rinses with cold DPBS.
RESULTS
Establishment of Primary Culture
The whole cord blood mononuclear fractions were cul-
tured. Over the ﬁrst 3 to 4 weeks in culture there was death
of a majority of the cells, with the macrophage/monocyte
lineage cells being the longest surviving of the hemato-
poietic component. The use of a low-glucose medium and
an acidic environment facilitated the elimination of the
hematopoietic progenitors. After 4 weeks in culture, UCB
NHPs were identiﬁable as colonies of adherent cells with a
ﬁbroblastlike appearance, similar to the MSCs isolated from
BM (Figure 1). Compared to BM MSCs, cord blood NHP
cultures were slower to establish, but, once established,
growth was maintained over multiple passages. Early in cul-
ture, both adherent and nonadherent cells were capable of
generating long-term adherent lines.
Figure 1. Morphology of UCB NHPs is similar to that of BM-derived MSCs. Inverted phase contrast light microscope images of cord blood pri-
mary culture, day 32 (A) and passage 3, day 62 (B); BM primary culture, day 14 (C) and passage 3, day 52 (D). Original magniﬁcation, 200×.
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The NHPs were passaged when the cells approached
50% to 60% conﬂuence by trypsinization and replated at a
concentration of 1000 to 2000 cells/cm2. The cells were
maintained in continuous culture for more than 10 months
and beyond 10 passages. The very early identification of
UCB NHPs was difficult. The growth rate was initially
slow, but then increased between passages 4 through 7
before slowing significantly after passage 9 or 120 days in
culture under these conditions. Total expansion over 10 pas-
sages was extrapolated to be in the range of 109 cells per
colony (Figure 2). Comparatively, it has been reported that
Osiris BM MSCs will undergo 19 to 21 population dou-
blings from the original cell [9].
Precursor Frequency
There was variability in the number of precursors in
individual UCB units. The precursor frequency of UCB
NHPs was measured by serial dilution using 96-well plates
(n = 3 expt). With this technique the precursor frequency
was found to be 1:950,000 MNCs plated (range, 0.7-2.8
precursors per 106 UCB MNCs). When cells were plated
into tissue culture flasks at a standard density of 1 × 106
MNCs/cm2, the measured frequency was more variable,
ranging from 0.05 to 1 NHP per 106 UCB MNCs plated (n
= 26 cords). Unlike BM mesenchymal progenitor colonies,
which were usually identiﬁable by 5 to 7 days in culture, the
UCB colonies were visible 4 to 8 weeks in culture.
Characterization by Flow Cytometry
UCB NHPs were large and required signiﬁcant adjust-
ment of ﬂow cytometer gating established for lymphocytes.
Their length ranged from 0.1 mm to 0.7 mm when adherent
to a tissue culture ﬂask. Expression of cell surface antigens
was evaluated by flow cytometry on both UCB- and BM-
derived cells. The UCB NHPs failed to mark with hemato-
poietic antigens (CD34, CD45, CD14, CD2, CD3, CD15,
CD16, CD19, CD24, CD33, CD38, glycophorin A). Similar
to BM-derived MSCs, they were positive for the adhesion
molecules CD29, CD44, and CD13. Additionally, this cell
population did not express CD90, CD106, or CD146, but
was dimly positive for CD105 and CD166 (Figure 3, Table).
NHP Cultures Do Not Contain Hematopoietic CFUs
From the second passage onward there were no hemato-
poietic colonies (CFU-GM, CFU-GEMM, or BFU-E)
detectable on standard CFU assay.
Cord Blood NHPs Exhibit Osteogenic and Adipogenic
Potential
In the presence of an osteogenic induction medium con-
sisting of β-glycerol phosphate, ascorbic acid, and dexam-
ethasone, the UCB NHPs dramatically increased their
expression of alkaline phosphatase and formed nodules of
hydroxyapatite (identiﬁed by Von Kossa staining), the latter
quantiﬁed by increased mineralized calcium in culture (Fig-
ure 4). The UCB NHPs do not take on the cuboidal
appearance typical of osteoblast-enriched cultures derived
from BM (Figure 4) [23].
After 2 weeks of culture in the adipogenesis medium,
neutral lipid vacuoles were apparent in the cytoplasm of
both UCB- and BM-derived cells. These vacuoles stained
with Oil Red O, confirming fat content. The vacuoles in
UCB NHPs were present in earlier-passage cells (passage
2-4) but not in later-passage cells (passage 7, 8). Adipogene-
sis in the BM cells was not dependent on the length of time
in culture.
Cord Blood NHPs Express Neural-Specific Antigens
UCB NHPs can be induced to express neural-specific
antigens. When exposed to hEGF/bFGF for 1 week, both
UCB NHPs and BM MSCs morphologically appear to take
on some of the features of neural cells in culture, such as
long bipolar extensions and branching ends. When com-
pared with immortalized neural progenitor cells, both the
UCB and BM cells demonstrated longer bipolar extensions,
both before and after exposure to neural differentiation fac-
tors. After neural culture, nearly all cells from both the
UCB NHPs and BM MSCs coexpressed the cytoskeletal
proteins found in neurons, β-tubulin III (TuJ1), and astro-
cytes, glial ﬁbrillary acidic protein (GFAP) (Figure 5). The
BM cells expressed these markers constituitively in the stan-
dard growth media, whereas the UCB NHPs expressed the
markers only after culture in the neural differentiation
Figure 2. Total extrapolated growth over time demonstrates varied rates of growth.
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media. The immunoﬂuorescent ﬁndings were conﬁrmed by
Western immunoblots for TuJ1 and GFAP (Figure 6).
DISCUSSION
The nonhematopoietic cellular component of BM con-
tains a cell population that is of great interest for its hemato-
logic support capacity and potential immune regulation.
Recently it has become apparent that there are cells within
that population that are able, in culture, to differentiate into
cell phenotypes of not only mesenchymal but also ectodermal
lineage. Initially these cells were termed mesenchymal stem
cells (MSCs). We feel this nomenclature is problematic given
the extended lineage differentiation capacity and given that
they have not been shown to be true stem cells [24]. Thus we
have chosen to use the term “nonhematopoietic progenitor”
(NHP) for these cells isolated from cord blood.
We have demonstrated that umbilical cord blood contains
a small population of NHPs that are capable of differentiating
into cells with bone, fat, and neural features in tissue culture.
Because the precursor frequency is low (ranging from 0.05 to
2.8 NHPs per 106 MNCs plated) and the initial culture phase
requires 1 to 2 months, these cells were not detected in the
standard CFU-F assay (when colonies are counted on day
14). This precursor frequency was lower than BM MSCs,
which have been reported in the range of 2 to 5 MSCs per
106 BM MNCs plated [19]. Despite the low initial frequency
in cord blood, UCB NHPs have tremendous expansion
capacity in culture. Calculated expansion potential can be in
the range of 1010 cells/cord, which is in the range of doses
used in therapeutic trials of MSC infusions (referred to as
mesenchymal stem cell therapy) [19].
However, our studies have raised more questions than
they answer. Is this cell population, isolated from UCB, the
same as that described from BM-derived nonhematopoietic
cells? Is the coexpression of multiple lineage antigens a
demonstration of lineage speciﬁcity or merely an artifact of
culture? Is this a unique stem cell, a cell population with
transdifferentiation capacity, or merely an epiphenomenon
of tissue culture? Finally, independent of these questions,
can this population be of therapeutic use?
There are many similarities between the NHPs isolated
from cord blood and the MSCs from BM. Both lack hemato-
poietic antigens and do not form hematopoietic cells in short-
term colony assays. Nieda and colleagues have demonstrated
the presence of endothelial precursors from highly puriﬁed
CD34+ UCB cells [25]. UCB NHPs are CD34– once cultures
are established. We have no information about their cell of
origin or whether they arise from the same stem cell as
hematopoietic cells. The ability of UCB NHPs to either dif-
ferentiate into hematopoietic cells in long-term assays or sup-
port long-term colony assays is currently under investigation.
Both UCB and BM populations respond to lineage-
speciﬁc signals and take on lineage-speciﬁc features. How-
ever, the differences between cord blood NHPs and BM-
derived MSCs are intriguing. When we looked at early
markers of bone and neural commitment (neural- and bone
lineage–specific antigen expression), we found that BM-Figure 3. Comparison of cell surface antigen expression between
UCB NHPs, BM MSCs and Osiris MSCs.
Comparison of Adhesion Molecule Expression Between BM MSCs, Osiris BM
MSCs, and UCB NHPs
UCB NHPs BM MSCs Osiris MSCs
CD13 + + + + + +
CD29 + + + + + +
CD44 + + + + + +
CD90 Thy1 - + + dim
CD105 SH-2, endoglin dim + + + 
CD106 VCAM-1 - - -
CD146 endothelial - - -
CD166 SB-10, ALCAM dim + + 
preosteoblast
H.S. Goodwin et al.
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derived cells, under our culture conditions, constitutively
express these markers without stimulation. However, UCB
NHPs express them only after culture in differentiation
media. The inducible expression of lineage characteristics in
UCB NHPs raises the issue as to whether the population
isolated from cord blood is more primitive or perhaps is
more responsive to local differentiation signals. If so, the
cord blood NHPs may have preferred characteristics when
considering source cells for therapeutic use.
The definition of MSCs is hampered by the lack of a
speciﬁc cell surface marker that deﬁnes the progenitor pop-
ulation. We have demonstrated the lack of hematopoietic
marker expression, speciﬁcally monocyte/macrophage mark-
ers, as well as the inability to form hematopoietic colonies
from the NHP population. The pattern of expression of
adhesion molecules is similar in UCB NHPs and BM
MSCs, with the exception of CD90. Interestingly CD90
expression was not inducible in UCB NHPs by exposure to
neural differentiation media (data not shown). CD166
(ALCAM), a marker for osteoblast precursors, is expressed
to a much lower degree in UCB NHPs than in BM MSCs.
For other markers, the expression is similar to that reported
by others for BM MSCs [9,21].
Critical questions about the nature of this cell population
were raised because of the coexpression of neuronal and glial
antigens. Is this an artifact of culture or has their genetic
program been redirected? This has signiﬁcant implications
given that neural cells are nonmesenchymal in origin. It is
important that under the neural culture conditions the
NHPs morphologically acquired features consistent with
cells of neural origin. A thorough evaluation of neurologic
function using clonal populations of NHPs is needed before
deﬁnitive conclusions about true neural cells being derived.
Although UCB NHPs were capable of expressing anti-
gens of multiple lineages, it will be important to demon-
strate that these cells can function across lineage boundaries
in vivo. Clearly, transplantation trials are needed to further
understand the capacity of these cells. From the sheep
xenograft model, Flake and colleagues have been able to
demonstrate durable engraftment of human BM-derived
MSCs even after immune competence has been achieved
[26]. Similar findings have been reported by others in
murine model systems [27,28].
Is this cell population a true stem cell? Stem cells are
defined as clonogenic, self-renewing progenitor cells that
can generate one or more specialized cell types [24]. The
assays presented in this paper were not performed on a
clonal level. Thus we cannot conclude that UCB NHPs
are a stem cell population, multiple differentiated pro-
genitors, or cells with transdifferentiation capacity.
Clonal assays combined with an in vivo demonstration of
site-specific function will be an important next step to
assist in understanding the physiologic importance of our
findings.
Irrespective of their current physiologic role, could this
cell population be used therapeutically to decrease graft-
versus-host disease or support more rapid hematopoietic
engraftment? There is great interest in the NHP population
as a possible transplantable source of tissue-specific cells.
Recent phase I trials of mesenchymal stem cell infusion by
Koç and Lazarus have demonstrated rapid recovery of
hematopoiesis following autologous BM MSC transplanta-
tion but have not been evaluable for survival of the infused
mesenchymal cells [19].
Figure 4. Expression of bone and fat phenotype after exposure of UCB NHPs to differentiation stimuli. Osiris BM-derived cells became cuboidal
when exposed to osteogenesis media, day 7 (A). UCB NHPs did not become cuboidal in the osteogenesis media, day 7 (B). UCB NHP osteogenesis
was evaluated by the expression of alkaline phosphatase, day 14 (C) and the formation of a mineralized matrix, day 14 (D). The calcium present was
extracted and the concentration measured over time (E). UCB NHP adipogenesis was detected by the presence of neutral lipid vacuoles, day 14 (F).
Original magniﬁcation: A, B, D, 200×; C, 100×; F, 400×.
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Figure 5. Pattern of expression of neural speciﬁc antigens in UCB NHPs and BM MSCs: constitutive expression in the BM MSCs. Dual staining with
TuJ1 (secondary antibody–Alexa Fluor 430) and GFAP (secondary antibody–Oregon Green) demonstrates that UCB NHPs in neural induction
medium express GFAP (A) and TuJ1 (B). UCB NHPs in standard medium do not express GFAP (C) or TuJ1 (D). BM MSCs in neural induction media
express GFAP (E) and TuJ1 (F). BM MSCs in standard medium constitutively express both GFAP (G) and TuJ1 (H). Original magniﬁcation, 400×.
H.S. Goodwin et al.
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Cord blood NHPs, given the ease in collection, bank-
ing, and availability compared to marrow, might offer an
added potential therapeutic advantage. Whether these cells
represent plasticity of gene expression driven by environ-
mental signals or a true progenitor cell needs further explo-
ration. These UCB-derived cells are intriguing as a poten-
tial source of cells for multiple organ cellular therapeutics.
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Figure 6. Neural antigen expression conﬁrmed by Western immuno-
blot for TUJ1 and GFAP. Lane 1, BM MSCs in standard growth
medium; lane 2, UCB NHPs in standard growth medium; lane 3, posi-
tive control; lane 4, UCB NHPs in neural induction medium.
